Alle Fälle anzeigen
UPC APP 60996/2024
—·EP4026488: TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Beklagte
- Abbott Laboratories
- Abbott Diabetes Care Inc.
- Abbott GmbH
- Abbott Diagnostics GmbH
- Abbott Laboratories GmbH
- Abbott Logistics B.V.
- Abbott France (S.A.S.)
- Abbott s.r.l.
- Abbott Gesellschaft m.b.H.
- Abbott B.V.
- Abbott (S.A./N.V.)
- Abbott Scandinavia Aktiebolag
- Abbott Oy
Vertreter: Dietrich Kamlah (Taylor Wessing); Christian Lederer (Taylor Wessing); Gisbert Hohagen (Taylor Wessing) - Division
- Dusseldorf LD
- Richter
- —
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 20. Nov. 2024
Entscheidungen
- 2024-11-20Generic application
Düsseldorf Local Division procedural order extending the time limit for DexCom Inc. to file its Rejoinder to the Counterclaim for Revocation and Reply to Application to Amend until 11 December 2024, in DexCom v. Abbott entities (EP 4 026 488). The extension was granted on grounds of fairness/equity because the previous time period for defendants had been similarly extended with claimant's consent.
Rechtsfragen:Extension of time limits (R. 9.3(a) RoP)Fairness in setting equal procedural deadlines
Dokumente
- BB566235706F9F1CDDC239781D21203D_en.pdf2024-11-20ENGLISH